

August 9, 2022



Lexaria Bioscience Corp. (NASDAQ: LEXX) Developing Powerful Tech to Treat Hypertension

NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- via [InvestorWire](#) — **Lexaria Bioscience Corp. (NASDAQ: LEXX)** today announces its placement in an editorial published by [NetworkNewsWire](#) ("NNW"), one of 50+ trusted brands within the [InvestorBrandNetwork](#) ("IBN"), a multifaceted financial news and publishing company for private and public entities.

To view the full publication, "The Power of Science to Stop a Killer," please visit:
<https://nnw.fm/9kD5b>

Nearly half of all American adults suffer from hypertension (high blood pressure), often referred to as a silent killer. More than 114 million adults in this country are at risk from damage caused by the long-term force of blood beating against artery walls, which often leads to disease and death. The good news is that hypertension is treatable and manageable through lifestyle changes and medications. Fact is, there are several approved blood pressure medications on the market, yet only about one in five people diagnosed with hypertension take medication. Why so few? Unfortunately, the side effects of these medications often outweigh the benefits.

However, a new hypertension blockbuster may be imminent. A safer, better-tolerated drug candidate just marked a major milestone on the path to approval and commercialization. A global innovator in drug-delivery platforms, **Lexaria Bioscience Corp. (NASDAQ: LEXX)** has been quietly progressing through clinical processes and amassing a growing body of evidence that strongly supports use of its patented DehydraTECH(TM) technology in hypertension therapeutics.

About Lexaria Bioscience Corp.

Lexaria's patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients ("APIs") enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids and nicotine by up to five to ten times, reduce time of onset from one to two hours to minutes, and mask unwanted tastes; the innovative tech is also being evaluated for orally administered anti-viral drugs, nonsteroidal anti-inflammatory drugs ("NSAIDs"), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with

25 patents granted and more than 50 patents pending worldwide.

For more information about the company, visit at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company's newsroom at <https://ibn.fm/LEXX>

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) [NetworkNewsBreaks](#) that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness.

NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text "STOCKS" to 77948 (U.S. Mobile Phones Only)

For more information please visit [https://www.NetworkNewsWire.com](http://www.NetworkNewsWire.com)

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: <http://NNW.fm/Disclaimer>

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the [InvestorBrandNetwork](#)



Source: Lexaria Bioscience Corp.